Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > The Ball is in THTX's Court
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(33)
•••
Comment by FredTheVoiceon Jan 11, 2021 10:15am
157 Views
Post# 32266359

RE:RE:RE:RE:RE:The Ball is in THTX's Court

RE:RE:RE:RE:RE:The Ball is in THTX's CourtMuslix, I am not saying you are wrong, but think about that........

After more than two years of negative vibe, even if the news were relatively good, we are now back (because we all were wrong about the turning point.......because its NOW), we are back in the POSITIVE ERA, POSITIVE CIRCLE or wathever you want to call it...........news will be climbing one after the other, investors will jump in, cheetos lover will fall off their chair saying a couple of weeks behind the curtains: "Oh, yesss, share price will be ...target.....crunch crunch.....will be 16$C in a year......crunch crunh...."

So, I dont want a buyout......

I want like just before TROGARZO FDA GO.....

I want to enjoy the ride in the next two years.....

What do you think ? You are the guy telling me to be patient with the ride to 30$C.....

FTV.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities